Clinical Trials Logo

Cesarean Section During Labor clinical trials

View clinical trials related to Cesarean Section During Labor.

Filter by:
  • None
  • Page 1

NCT ID: NCT02794779 Recruiting - Clinical trials for Cesarean Section During Labor

Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial

MODCL
Start date: July 2016
Phase: Phase 3
Study type: Interventional

Introduction: postpartum hemorrage is a leading cause of death after cesarean sections in Brazil. Oxytocin is the main drug for both prophylaxis and threatment of postpartum hemorrage because uterine atony is the most prevalent cause. Both excessive and too low oxytocin doses threaten the life of women. Objective: to determine the minimum effective dose of oxytocin for cesareans during labor. Method: adaptative clinical trial using a modified up and down method of two sequential groups: rule of three and continuous infusion. Allocation in rule of three or continuous infusion will be random and masked for patients and anesthesiologists. The minimum effective dose will be the effective dose for 90% of success (ED90 for preventing uterine atony).